ABSTRACT
In January 1999, Miles White became the new CEO of Abbott Laboratories, and in June, was made chairman of the board. White had plans to transform Abbott into a major player on the international stage, leveraging its core competencies in pharmaceutical development to focus on its primary area of expertise and commitment: HIV/AIDS. 1 Over the next decade, White would increase the global presence of Abbott through both internal innovation and intelligent acquisitions. And he would transform the company’s foundation, Abbott Fund, into a significant global contributor in the fight against AIDS in the developing world.
